Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations

Show other versions (1)

Neutropenia and associated infection, resulting in hospitalization and use of antibiotics, has a negative effect on chemotherapy. The need to reduce the dose of cytotoxic drugs during neutropenia leads to lower survival rates in patients with hematological malignancies and solid tumors. Since 1990s...

Full description

Bibliographic Details
Main Authors:	V. V. Ptushkin, N. V. Zhukov, V. I. Borisov, S. V. Minenko, Yu. V. Larina
Format:	Article
Language:	Russian
Published:	ABV-press 2015-06-01
Series:	Onkogematologiâ
Subjects:	chemotherapy dose intensity toxicity neutropenia granulocyte colony stimulating factor pegfilgrastim lipegfilgrastim lonkvex
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/143

Similar Items

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
by: Guariglia R, et al.
Published: (2016-01-01)

Experience in prevention of neutropenia in patients with disseminated soft tissue sarcomas receiving polychemotherapy
by: L Yu Vladimirova, et al.
Published: (2016-09-01)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
by: Esse I. H. Akpo, et al.
Published: (2017-09-01)

Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
by: Vineet Talwar, et al.
Published: (2017-01-01)

Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01)

Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01)

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study
by: Derek Weycker, et al.
Published: (2019-08-01)

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
by: Patrick Wayne Cobb, et al.
Published: (2020-09-01)

Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
by: I. B. Kononenko, et al.
Published: (2020-11-01)

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
by: Ghidini M, et al.
Published: (2016-06-01)

Clinical manifestations and outcomes of pediatric chronic neutropenia
by: Chuan Wan, et al.
Published: (2012-04-01)

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges
by: Yi Ba, et al.
Published: (2020-11-01)

Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01)

Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01)

Simultaneous treatment with carbimazole and granulocyte-colony stimulating factor in a patient with thyrotoxicosis and carbimazole induced neutropenia
by: Talapatra Indrajit, et al.
Published: (2006-12-01)

Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic
by: Wei C, et al.
Published: (2021-04-01)

Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis
by: Giovanni Rosti, et al.
Published: (2011-09-01)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
by: Yosuke Dotsu, et al.
Published: (2021-09-01)

Modern concepts of biosimilars in hematology and oncology
by: V. V. Ptushkin
Published: (2014-07-01)

Modern concepts of biosimilars in hematology and oncology
by: V. V. Ptushkin
Published: (2014-07-01)

Localized Pegfilgrastim-induced Neutrophilic Dermatosis with Tissue G-CSF Expression: A Mimicker of Sweet’s Syndrome
by: Toshio Ichiki, et al.
Published: (2019-04-01)

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
by: Zsuzsanna Kahan, et al.
Published: (2019-02-01)

Recombinant Ganoderma lucidum Immunomodulatory Protein Improves the Treatment for Chemotherapy-Induced Neutropenia
by: Xinhua Lei, et al.
Published: (2020-06-01)

Study of PEG-Filstim sub-acute toxicity
by: V. L. Karbovskyi, et al.
Published: (2018-08-01)

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
by: Kalpna Desai, et al.
Published: (2018-09-01)

Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting
by: Axel S. Merseburger, et al.
Published: (2021-05-01)

Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
by: Alshari O, et al.
Published: (2021-09-01)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01)

Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report
by: Hikari Jimbo, et al.
Published: (2021-08-01)

Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil
by: Yu Ohkura, et al.
Published: (2019-07-01)

Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature
by: Hideko Hoshina, et al.
Published: (2019-12-01)

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety
by: Reshma Mahtani, et al.
Published: (2021-05-01)

The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
by: Editorial Board
Published: (2021-08-01)

Chronic Refractory Uveitis in a Patient with Childhood-Onset Cyclic Neutropenia
by: Li-Li Chen, et al.
Published: (2011-05-01)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
by: Ka‐Won Kang, et al.
Published: (2020-09-01)

Efficacy of recombinant human granulocyte colony stimulating factor in very-low-birth-weight infants with early neutropenia
by: Ru-Jeng Teng, et al.
Published: (2015-02-01)

The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy
by: Jie Chen, et al.

Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
by: Inna P. Ganshina, et al.
Published: (2021-02-01)